Lifestyle changes along with changes in
eating habits lead to obesity, which causes accumulation of excessive
fat and cholesterol, resulting in increase in body weight. Obesity is a
problem around the world that affects a large number of people. Rising
incidences of obesity are increasing the risk of developing deep vein
thrombosis (DVT). Deep vein thrombosis (DVT) refers to the formation of a
blood clot, also known as a thrombus, in one of the body’s large veins,
most commonly in the lower limbs. The most serious complication that
can arise from DVT is a pulmonary embolism (PE), which occurs in over
one-third of DVT patients. According to a study by Centers for Disease
Control and Prevention, among the patients who have had a DVT, one-half
is likely to have long-term complications (post-thrombotic syndrome)
such as swelling, pain, discoloration, and scaling in the affected limb.
Deep vein thrombosis can also occur in patients who have undergone a
surgery, broken limbs, history of heart attack, and cancer.
Changing lifestyle habits in the
developed as well as developing countries, rising obese population, and
growing health care expenditure are some of the factors fuelling the
global deep vein thrombosis market during the forecast period. It has
been observed that DVT is more prevalent among the population above the
age of 65 years. The increasing geriatric population is projected to be a
primary reason for the growth of the global market in the near future.
The developing countries around the world are currently undergoing a
paradigm shift and are investing a large amount of government funds in
the research and development, which is likely to drive the market
growth. However, complex pathophysiology of the disease, high cost of
treatment, and side effects associated with it act as key restraints for
the deep vein thrombosis market growth.
Global deep vein thrombosis market is
segmented on the basis of treatment, distribution channel, and
geography. In terms of treatment, the market is segmented into blood
thinners, clot busters, inferior vena cava filters, and compression
stockings. The blood thinners segment is anticipated to hold a major
share of the market during the forecast period owing to rise in the use
of heparin, the oldest and widely used anticoagulant drug, and the
development of novel oral anticoagulants (NOACs) to overcome the
limitation of current treatment options and provide improved patient of
care.
On the basis of distribution channel, the
market is segmented into hospital pharmacy, retail pharmacy, and
e-commerce. The retail pharmacy is anticipated to hold a significant
market share while the e-commerce segment is expected to grow at a high
CAGR during the forecast period. Rising digitalization, increased per
capita income, and growing awareness about the online pharmacy sector in
the developed as well as developing regions are factors which are
projected to contribute to the market growth of the e-commerce segment
in the near future.
In terms of geography, the deep vein
thrombosis market is distributed over North America, Europe, Asia
Pacific, Latin America, and Middle East & Africa. North America
dominates the deep vein thrombosis market due to a high incidence and
prevalence rate of the condition, increase in the demand for advance
treatment, and rise in geriatric population. It is followed by Europe.
Asia Pacific is an emerging market for deep vein thrombosis due to the
developing health care infrastructure and rising government expenditure
in the health care industry. Increasing geriatric population base,
rising prevalence of chronic diseases, and rapid growth in foreign
investments are expected to propel the growth of the market in
developing nations of the Middle East and Asia Pacific. However,
affordability issues, lack of proper treatment, and poor patient
education are restraining the growth of the market in Middle East &
Africa and Latin America.
Major players operating in the deep vein
thrombosis market include Bristol-Myers Squibb Company, Sanofi-Aventis,
Pfizer, Inc., Daiichi Sankyo Co. Ltd., Johnson & Johnson, Abbott
Laboratories, Merck & Co., and Astellas Pharma Inc.
No comments:
Post a Comment